The case was originally filed in 2013 and has already taken two trips to the Second Circuit Court of Appeals. The certified class of End-Payors accuse Takeda of violating the law by “misdescribing” its patent rights to the FDA. Plaintiffs allege that Takeda unlawfully engaged in anticompetitive and monopolistic conduct which inflated the price of its diabetes treatment, Actos (pioglitazone), by delaying the entry of generic alternatives and causing inflated…
PA Philadelphia | 866-540-5505
NY New York City | 866-540-5505
NY New York City | 866-540-5505
NY New York City | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
CA San Francisco | 866-540-5505
FL Fort Lauderdale | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
CT Chester | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
CA Los Angeles | 866-540-5505
CA Los Angeles | 866-540-5505
CT Chester | 866-540-5505
CT Chester | 866-540-5505
FL Fort Lauderdale | 866-540-5505
CT Chester | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
CA San Diego | 866-540-5505
PA Philadelphia | 866-540-5505
CT Chester | 866-540-5505
NY New York City | 866-540-5505
NY New York City | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
PA Philadelphia | 866-540-5505
FL Fort Lauderdale | 866-540-5505
NJ Hoboken | 866-540-5505
NY New York City | 866-540-5505
PA Philadelphia | 866-540-5505
PA Philadelphia | 866-540-5505
PA Philadelphia | 866-540-5505
NY New York City | 866-540-5505
CT Chester | 866-540-5505
PA Philadelphia | 866-540-5505
CA San Diego | 866-540-5505
PA Philadelphia | 866-540-5505
PA Philadelphia | 866-540-5505
PA Philadelphia | 866-540-5505
CA Los Angeles | 310-203-0600